Premium
Benefits of and Barriers to Pharmacogenomics‐Guided Treatment for Major Depressive Disorder
Author(s) -
Ahmed Ahmed T.,
Weinshilboum Richard,
Frye Mark A.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1009
Subject(s) - pharmacogenomics , major depressive disorder , antidepressant , medicine , psychiatry , adverse effect , drug , intensive care medicine , pharmacology , mood , anxiety
Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug‐related side effects and treatment resistance continue to present major challenges.[1][Trivedi, M.H., 2006] Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall “value equation,” and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.